FDA OKs new use of J&J’s Darzalex

The FDA approves the use of Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech’s Darzalex (daratumumab) to treat adults with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy.

Janssen in-licensed global rights to CD38-directed cytolytic antibody from Genmab A/S (NASDAQ:GMAB) in August 2012.

Darzalex accounted for 8.4% of JNJ’s Q2 pharmaceutical sales ($901M/10,752M).

https://seekingalpha.com/news/3607686-fda-oks-new-use-of-j-and-js-darzalex